Brainomix’s e-Lung AI imaging software has been selected by Boehringer Ingelheim to provide quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint in a phase III study for interstitial lung disease (ILD).
The DROP-FPF trial is a phase IIIB double-blind, randomized, placebo-controlled study investigating the safety and effectiveness of nerandomilast (Jascayd) in people with interstitial lung abnormalities and a family history of pulmonary fibrosis. It is the first phase III trial to use automated, quantitative HRCT imaging biomarkers, according to Brainomix.
The study, which is set to begin enrolling patients in January, will investigate whether early intervention with nerandomilast slows the progression of early signs of pulmonary fibrosis in people with a family history of the condition. It will include a two-year follow-up period, according to Brainomix.
Nerandomilast received U.S. Food and Drug Administration (FDA) approval for both idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in December, 2025.
Trained on large and diverse datasets of patients with different forms of ILD, e-Lung was validated in the phase III INBUILD study, which led to the approval of nintedanib (Ofev) for patients with progressive pulmonary fibrosis, the firm added.
